All In Biotech

Drug Trial Radar · NCT07554339

A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)

A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Study of MK-1084 Plus Durvalumab Versus Placebo Plus Durvalumab in Participants With Locally Advanced, Unresected KRAS G12C-Mutant Non-Small Cell Lung Cancer Without Disease Progression Following Definitive Platinum-Based Chemoradiotherapy (KANDLELIT-015)

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 310 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

310

Planned (sponsor's estimate)

Start

Jun 18, 2026

Primary completion

Dec 15, 2032

Study completion Aug 17, 2037

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Apr 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for new ways to treat locally advanced non-small cell lung cancer (NSCLC) that is unresected and has a gene mutation called KRAS G12C. Researchers want to learn if calderasib (MK-1084) can be given with durvalumab, an immunotherapy, to treat NSCLC after chemotherapy and radiation therapy. The goal of this trial is to learn if participants who receive calderasib and durvalumab live longer without the cancer growing or spreading compared to participants who receive placebo and durvalumab.

Conditions

  • Non-small Cell Lung Cancer

Interventions

  • CalderasibDrug

    Tablet for oral administration.

  • DurvalumabBiological

    Solution for intravenous (IV) infusion.

  • Placebo to MK-1084Other

    Placebo to MK-1084.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS)Time frame: Up to approximately 6 years

Locations

119 sites in 18 countries. Site status is shown where the registry gives one.

  • Piedmont Atlanta Hospital ( Site 0121)

    Atlanta, Georgia · Recruiting

  • Low Country Cancer Care ( Site 0155)

    Savannah, Georgia · Recruiting

  • Duly Healthcare ( Site 0158)

    Lisle, Illinois · Recruiting

  • NHO Revive Research Institute LLC ( Site 0118)

    Lincoln, Nebraska · Recruiting

  • Rutgers Cancer Institute of New Jersey ( Site 0100)

    New Brunswick, New Jersey · Recruiting

  • New York Oncology Hematology P.C ( Site 9000)

    Albany, New York · Recruiting

  • WakeMed Raleigh Campus ( Site 0144)

    Raleigh, North Carolina · Recruiting

  • Virginia Cancer Specialists ( Site 0114)

    Fairfax, Virginia · Recruiting

  • Hospital Italiano de Buenos Aires. ( Site 0300)

    Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina · Recruiting

  • Clinica Adventista Belgrano ( Site 0304)

    Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina · Recruiting

  • Instituto Alexander Fleming ( Site 0301)

    Ciudad Autonoma de Buenos Aires., Buenos Aires, Argentina · Recruiting

  • Instituto de Investigaciones Clínicas Mar del Plata ( Site 0303)

    Mar del Plata, Buenos Aires, Argentina · Recruiting

  • Hospital Britanico de Buenos Aires ( Site 0305)

    Buenos Aires, Buenos Aires F.D., Argentina · Recruiting

  • Sanatorio Parque ( Site 0302)

    Rosario, Santa Fe Province, Argentina · Recruiting

  • Northern Beaches Hospital ( Site 2401)

    Frenchs Forest, New South Wales, Australia · Recruiting

  • Mater Misericordiae Limited ( Site 2402)

    South Brisbane, Queensland, Australia · Recruiting

  • Princess Alexandra Hospital ( Site 2406)

    Woolloongabba, Queensland, Australia · Recruiting

  • Frankston Hospital ( Site 2403)

    Frankston, Victoria, Australia · Recruiting

  • CRIO - CENTRO REGIONAL INTEGRADO DE ONCOLOGIA ( Site 0406)

    Fortaleza, Ceará, Brazil · Recruiting

  • AFECC ASSOCIACAO FEMININA EDUCACAO COMBATE CANCER ( Site 0416)

    Vitória, Espírito Santo, Brazil · Recruiting

  • Irmandade da Santa Casa de Misericórdia de Porto Alegre ( Site 0415)

    Porto Alegre, Rio Grande do Sul, Brazil · Recruiting

  • CEPON ( Site 0413)

    Florianópolis, Santa Catarina, Brazil · Recruiting

  • Fundação Pio XII - Hospital de Câncer de Barretos ( Site 0401)

    Barretos, São Paulo, Brazil · Recruiting

  • Anhui Provincial Cancer Hospital ( Site 2209)

    Hefei, Anhui, China · Recruiting

  • Beijing Cancer hospital ( Site 2217)

    Beijing, Beijing Municipality, China · Recruiting

  • Beijing Cancer hospital ( Site 2226)

    Beijing, Beijing Municipality, China · Recruiting

  • Beijing Peking Union Medical College Hospital ( Site 2220)

    Beijing, Beijing Municipality, China · Recruiting

  • Fujian Cancer Hospital ( Site 2232)

    Fuzhou, Fujian, China · Recruiting

  • Zhongshan Hospital Affiliated to Xiamen University ( Site 2213)

    Xiamen, Fujian, China · Recruiting

  • The First Affiliated Hospital of Xiamen University. ( Site 2239)

    Xiamen, Fujian, China · Recruiting

  • The First Affiliated Hospital of Guangzhou Medical University ( Site 2211)

    Guangzhou, Guangdong, China · Recruiting

  • The Second Affiliated Hospital of Guilin Medical University ( Site 2212)

    Guilin, Guangxi, China · Recruiting

  • Guangxi Medical University Cancer Hospital ( Site 2202)

    Nanning, Guangxi, China · Recruiting

  • Fourth Hospital of Hebei Medical University ( Site 2201)

    Shijiazhuang, Hebei, China · Recruiting

  • Union Hospital Tongji Medical College Huazhong University of Science and Technology-Medical Oncology ( Site 2206)

    Wuhan, Hubei, China · Recruiting

  • Hubei Cancer Hospital ( Site 2203)

    Wuhan, Hubei, China · Recruiting

  • The Second Xiangya Hospital Of Central South University ( Site 2207)

    Changsha, Hunan, China · Recruiting

  • Hunan Cancer Hospital ( Site 2214)

    Changsha, Hunan, China · Recruiting

  • Nanjing Drum Tower Hospital ( Site 2224)

    Nanjing, Jiangsu, China · Recruiting

  • Shandong Cancer Hospital ( Site 2200)

    Jinan, Shandong, China · Recruiting

Showing 40 of 119 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.